Doctor of Osteopathy Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Sunay Patel

Interventional Pain Medicine Lawrenceville, GA Doctor of Osteopathy

NPI 1417511858 CMS profile 11557554

455 Philip Blvd Ste 140, Lawrenceville, GA 30046

Open in the dashboard

General payments

$6,312

82 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sunay Patel of Lawrenceville, GA is reported in the CMS Open Payments database as having received $6,312 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,986 39
2024 General $2,152 20
2023 General $2,174 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sunay Patel
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Sunay Patel were reported at $1,986. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Sunay Patel Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $0 $605 $187–$1,924 $149
2023 $2,174 $671 $195–$1,915 $160
2024 $2,152 $684 $206–$1,837 $164
2025 $1,986 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Medtronic, Inc. $3,508 35 payments
  2. Curonix LLC $869 11 payments
  3. Forte Bio-Pharma LLC $650 12 payments
  4. ACADIA Pharmaceuticals Inc $246 4 payments
  5. Nevro Corp. $245 3 payments
  6. Boston Scientific Corporation $201 4 payments
  7. Saluda Medical Americas, Inc. $117 1 payment
  8. AstraZeneca Pharmaceuticals LP $103 1 payment
  9. Argenx US, Inc. $101 1 payment
  10. Foundation Fusion Solutions, LLC $72 2 payments
  11. Other $199 8 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,939 66 payments
  2. Travel and Lodging $2,354 15 payments
  3. Entertainment $19 1 payment
Products named General payments · program years 2023–2025
  1. KYPHON EXPRESS II KYPHOPAK TRAY $1,281 9 payments
  2. VANTA ADAPTIVESTIM $1,143 10 payments
  3. INTELLIS ADAPTIVESTIM $1,039 14 payments
  4. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $869 11 payments
  5. PROLATE Pain $650 12 payments
  6. PROLATE Pain $650 12 payments
  7. TANLOR $650 12 payments
  8. NALOCET $650 12 payments
  9. PROLATE Pain $650 12 payments
  10. NUPLAZID $246 4 payments
  11. Other $942 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,212

Median for Interventional Pain Management: 1,220

Drug cost

$92,484

Median for Interventional Pain Management: $39,344

Branded share of claims

58.7%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 323 $32,589
Belbuca Buprenorphine Hcl Brand 32 $22,296
Buprenorphine Generic 59 $13,908
Xtampza Er Oxycodone Myristate Brand 23 $9,322
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 285 $6,206
Oxycodone Hcl Generic 110 $2,158
Pregabalin Generic 106 $1,600
Tramadol Hcl Er Tramadol Hcl Brand 22 $1,327
Gabapentin Generic 71 $791
Morphine Sulfate Er Morphine Sulfate Brand 27 $640

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$17,517

Medicare's payments for the services billed

Medicare patients

127

Average age 68

Services billed

244

85 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Depression 35%
COPD 31%
Chronic kidney disease 30%
Ischemic heart disease 28%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record